IRLAB Therapeutics AB (OSTO:IRLAB A) Dividend Payout Ratio: 0.00 (As of Mar. 2026)


OSTO:IRLAB A IRLAB Therapeutics AB OSTO:IRLAB A
35 GF Score
Price kr1.22
GF Value kr11.78
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB Dividend Payout Ratio?

IRLAB Therapeutics AB OSTO:IRLAB A +0.16% 35 Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 35/100 and a GF Value™ of kr11.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 134 Biotechnology companies, IRLAB Therapeutics AB ranks worse than 746267.91% on this metric.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. IRLAB Therapeutics AB's Dividend Payout Ratio for the months ended in Mar. 2026 was 0.00.

The historical rank and industry rank for IRLAB Therapeutics AB's Dividend Payout Ratio or its related term are showing as below:


OSTO:IRLAB A's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.445
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-06-29), the Dividend Yield % of IRLAB Therapeutics AB is 0.00%.

IRLAB Therapeutics AB's Dividends per Share for the months ended in Mar. 2026 was kr0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


IRLAB Therapeutics AB (OSTO:IRLAB A) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


IRLAB Therapeutics AB Dividend Payout Ratio Related Terms


IRLAB Therapeutics AB Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for IRLAB Therapeutics AB's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB Dividend Payout Ratio Chart

IRLAB Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IRLAB Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OSTO:IRLAB A vs VRTX, REGN, ALNY: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, IRLAB Therapeutics AB's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Dividend Payout Ratio falls into.


OSTO:IRLAB A
35GF Score
IRLAB Therapeutics AB OSTO:IRLAB A
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IRLAB Therapeutics AB Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

IRLAB Therapeutics AB's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=0/ -1.605
=N/A

IRLAB Therapeutics AB's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ 0.108
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
IRLAB Therapeutics AB (OSTO:IRLAB A) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on IRLAB Therapeutics AB and its competitors. According to the industry distribution chart, IRLAB Therapeutics AB ranks #999999 out of 134 companies in the Biotechnology industry.
Is IRLAB Therapeutics AB's Dividend Payout Ratio too high?
IRLAB Therapeutics AB's current Dividend Payout Ratio is 0.00. Based on the distribution chart, IRLAB Therapeutics AB ranks #999999 out of 134 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IRLAB Therapeutics AB has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #999999 out of 134 companies for Dividend Payout Ratio. This places IRLAB Therapeutics AB in the lower half of its industry. The industry median Dividend Payout Ratio is 0.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on IRLAB Therapeutics AB and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRLAB Therapeutics AB's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.78, compared to a current price of kr1.22 — trading 89.6% below its estimated fair value. The current Dividend Payout Ratio is 0.00. IRLAB Therapeutics AB's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.22 is trading 89.6% below its estimated GF Value™ of kr11.78. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

  • Dividend Payout Ratio: 0.00
  • GF Value™: kr11.78 vs. price of kr1.22 (89.6% below fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IRLAB Therapeutics AB Business Description

Other Exchanges 6IRA:Germany
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
35GF Score

Get the complete analysis for OSTO:IRLAB A

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.22
Price
kr11.78
GF Value